Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics Inc is developing TH103, a novel anti-VEGF drug that demonstrates superior retinal retention compared to existing treatments like Eylea, suggesting enhanced durability for patient outcomes. The company’s promising preclinical findings, including the complete inhibition of VEGF-induced endothelial cell proliferation, underscore the potential for TH103 to outperform current therapies in treating prevalent retinal diseases. Additionally, the success of competing drugs like Vabysmo, which has generated over $4 billion in global sales, highlights the substantial market potential for innovative anti-VEGF therapies, positioning Kalaris Therapeutics favorably within this expanding arena.

Bears say

Kalaris Therapeutics Inc., being a development-stage biopharmaceutical company, faces substantial financial risks as it has yet to commercialize any products, which will require investment in infrastructure for the potential launch of its lead drug, TH103. The company is expected to continue incurring net losses until commercialization at best, with the protracted timelines for clinical development, regulatory approvals, and potential market competition further exacerbating its financial outlook. Additionally, Kalaris has no revenue-generating products and has accumulated significant losses since its inception, contributing to a negative perspective on its financial viability.

Allovir Inc (KLRS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 4 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.